

# ONJ UPDATE 2024

## Torino, 24 febbraio 2024

### Abstract Submission FORM

**CLINICAL AND PHARMACOLOGICAL EVALUATION IN THE SURGICAL TREATMENT OF PATIENTS WITH DRUG-RELATED OSTEONECROSIS OF THE JAWS**

SECTION: 4A

AUTHORS (max 8): Contrassegnare SPEAKER con “\*”

Negrini S<sup>1\*</sup>, Daleffe F<sup>1</sup>, Bocchialini G<sup>1</sup>, Ferrari L<sup>1</sup>, Salgarello S<sup>2</sup>, Visconti L<sup>2</sup>, Audino E<sup>2</sup>, Castellani A<sup>1</sup>

**AFFILIATION:**

1. Maxillo-Facial Surgery Unit – ASST Spedali Civili Brescia
2. School of Dentistry, University of Brescia

**Background.**

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab therapy.

The purpose of our study, which reviews our experience in patients treated surgically for drug-related onj of the jaws, is aimed at assessing the possible incidence of recurrence as a function of the drug used in neoplastic treatment

**Patients and methods.**

The sample analyzed was 109 patients of whom 75 were treated with bisphosphonates and 34 with denosumab.

The inclusion criteria is related to the severity of the pathology ( studied patients at stage 2 and 3 according to SICMF – SIPMO classification) who took exclusively bisphosphonates or denosumab for bone secondarisms.

The study also considered the duration of treatment of patients included in the sample under review.

**Results.**

There were 17 recurrences of which 11 in treated with bisphosphonates and 6 with denosumab.

**Conclusions.**

Although few variables related to the pathology under study were considered showed that there were no differences in terms of post-surgical recurrence of patients who took these drugs for cancer therapy.

**REFERENCES:**

1. Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). *BMC Pharmacol Toxicol.* 2023 Mar 6;24(1):15. doi: 10.1186/s40360-023-00657-y. PMID: 36879299; PMCID: PMC9987072.
2. Laputková G, Talian I, Schwartzová V. Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis. *Int J Mol Sci.* 2023 Nov 25;24(23):16745. doi: 10.3390/ijms242316745. PMID: 38069068; PMCID: PMC10706386
3. Campisi G, Bedogni A, Fusco V *Raccomandazioni clinico-erapeutiche sull'osteonecrosi delle ossa mascellari (onj)*farmaco-re-